105 related articles for article (PubMed ID: 21697045)
1. Efficacy of taxane regimens in patients with metastatic angiosarcoma.
Hirata T; Yonemori K; Ando M; Hirakawa A; Tsuda H; Hasegawa T; Chuman H; Namikawa K; Yamazaki N; Fujiwara Y
Eur J Dermatol; 2011; 21(4):539-45. PubMed ID: 21697045
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
Jones SE; Erban J; Overmoyer B; Budd GT; Hutchins L; Lower E; Laufman L; Sundaram S; Urba WJ; Pritchard KI; Mennel R; Richards D; Olsen S; Meyers ML; Ravdin PM
J Clin Oncol; 2005 Aug; 23(24):5542-51. PubMed ID: 16110015
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
4. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Yonemori K; Katsumata N; Uno H; Matsumoto K; Kouno T; Tokunaga S; Yamanaka Y; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2005 Feb; 89(3):237-41. PubMed ID: 15754121
[TBL] [Abstract][Full Text] [Related]
6. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital.
Lu CH; Lin YC; Chang HK
Chang Gung Med J; 2007; 30(1):33-40. PubMed ID: 17477027
[TBL] [Abstract][Full Text] [Related]
7. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.
Schlemmer M; Reichardt P; Verweij J; Hartmann JT; Judson I; Thyss A; Hogendoorn PC; Marreaud S; Van Glabbeke M; Blay JY
Eur J Cancer; 2008 Nov; 44(16):2433-6. PubMed ID: 18771914
[TBL] [Abstract][Full Text] [Related]
9. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Nabholtz JM; Crown J
Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
[TBL] [Abstract][Full Text] [Related]
10. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
[TBL] [Abstract][Full Text] [Related]
11. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.
Fury MG; Antonescu CR; Van Zee KJ; Brennan MF; Maki RG
Cancer J; 2005; 11(3):241-7. PubMed ID: 16053668
[TBL] [Abstract][Full Text] [Related]
12. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.
Italiano A; Cioffi A; Penel N; Levra MG; Delcambre C; Kalbacher E; Chevreau C; Bertucci F; Isambert N; Blay JY; Bui B; Antonescu C; D'Adamo DR; Maki RG; Keohan ML
Cancer; 2012 Jul; 118(13):3330-6. PubMed ID: 22045619
[TBL] [Abstract][Full Text] [Related]
13. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Radaideh SM; Sledge GW
Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer.
Kondoh C; Takahari D; Shitara K; Mizota A; Nomura M; Yokota T; Ura T; Ito S; Kawai H; Sawaki A; Muro K
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1511-5. PubMed ID: 23064062
[TBL] [Abstract][Full Text] [Related]
15. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients.
Nagano T; Yamada Y; Ikeda T; Kanki H; Kamo T; Nishigori C
Cancer; 2007 Aug; 110(3):648-51. PubMed ID: 17582627
[TBL] [Abstract][Full Text] [Related]
17. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
[TBL] [Abstract][Full Text] [Related]
18. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
[TBL] [Abstract][Full Text] [Related]
19. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
[TBL] [Abstract][Full Text] [Related]
20. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
